Sanofi subsidiary Genzyme agrees to pay $22.3 million to settle accusations that its sales rep encouraged off-label use of the Seprafilm surgical product.
Massachusetts-based Genzyme Corp., a subsidiary of Sanofi (NYSE:SNY), agreed to pay $22.3 million to settle a whistleblower lawsuit accusing the company of off-label marketing of its Seprafilm surgical product.
A pair of brokers plead guilty to charges of insider trading in Stryker Corp. stock ahead of its 2011 acquisition of Orthovita.
A pair of brokers pleaded guilty to federal insider trading charges yesterday, admitting that they used tips from a former Stryker (NYSE:SYK) marketing executive to make illicit trades ahead of the medical device company's 2011 acquisition of Orthovita.
Unilife shares are up more than 24% this week on news of a deal with MedImmune, the biologics arm of pharmaceuticals giant AstraZeneca.
Unilife (NSDQ:UNIS) shares are up more than 24% this week on a supply deal for its wearable injectors it inked with MedImmune, the biologics division of pharma giant AstraZeneca (NYSE:AZN).
Unilife CEO Alan Shortall says a pair of Forbes articles were "vindictive," "malicious" and a "slap in the face" to analysts and portfolio managers who put their trust in the company.
French healthcare giant Sanofi is the last buyer still in the running to acquire German Bayer's blood glucose management devices, a deal that may be worth more than $1.5 billion, sources say.
Johnson & Johnson, already the world's largest health products maker, could have its eye on Edwards Lifesciences and St. Jude Medical as potential acquisitions, analysts say.
Shire plc doubles down on its $750 million buyout of Advanced Biohealing with Pervasive Therapeutics and its endothelial cell technology; also, orthopedic bellwether Biomet's Q3 results signal sector growth; McKesson beats out rivals for $32B VA deal; Insulet expands OUS distribution deal; Revolutions Medical inks Korean distribution deal; Pluromed pays back $500k Mass. loan; plus, a Funding Roundup and analysts' ups and downs.
Shire (NSDQ:SHPGY) said it agreed to acquire Pervasis Therapeutics and its endothelial cell technology for an undisclosed amount.
, C.R. Bard
, ICU Medical Inc.
, Insulet Corp.
, Mass. Life Sciences Center (MLSC)
, McKesson Corp.
, Pluromed Inc.
, Revolutions Medical Corp.
, Shire Plc.
, Tearlab Corp.
, Advanced BioHealing Inc.